How many insider trades does FilingIQ track for ASND?

FilingIQ tracks 8 Form 4 insider transactions for ASND (Ascendis Pharma A/S), covering filings from May 11, 2026 onwards. 8 of those were filed in the last 90 days.

Are ASND insiders net buyers or net sellers?

Across the full Form 4 history for ASND, 7 transactions (88%) were open-market purchases and 1 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ASND insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ASND in?

Ascendis Pharma A/S (ASND) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $13.38B.

ASND insider trading

NasdaqGS Healthcare

Ascendis Pharma A/S — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

88% / 13%

Market cap

$13.38B

About Ascendis Pharma A/S

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Company website: ascendispharma.com

ASND insider activity at a glance

FilingIQ has scored 8 insider transactions for ASND since May 11, 2026. The most recent filing in our index is dated Jun 2, 2026.

Across the full history, 7 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ASND insider trades is 58.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ASND trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,165

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

KYMR 178

Kymera Therapeutics, Inc.

First Tracks Biotherapeutics, Inc.

13F funds holding ASND

Avoro Capital Advisors LLC

$1.09B · 10.7% of AUM

PERCEPTIVE ADVISORS LLC

$350.28M · 6.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for ASND?: FilingIQ tracks 8 Form 4 insider transactions for ASND (Ascendis Pharma A/S), covering filings from May 11, 2026 onwards. 8 of those were filed in the last 90 days.
Are ASND insiders net buyers or net sellers?: Across the full Form 4 history for ASND, 7 transactions (88%) were open-market purchases and 1 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ASND insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ASND in?: Ascendis Pharma A/S (ASND) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $13.38B.

Methodology & sources

Every ASND insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.